HUP0103222A2 - Anyagcsere rendellenességek kezelésére alkalmas glükokortikoid és tiroid hormon receptor ligandumok - Google Patents
Anyagcsere rendellenességek kezelésére alkalmas glükokortikoid és tiroid hormon receptor ligandumokInfo
- Publication number
- HUP0103222A2 HUP0103222A2 HU0103222A HUP0103222A HUP0103222A2 HU P0103222 A2 HUP0103222 A2 HU P0103222A2 HU 0103222 A HU0103222 A HU 0103222A HU P0103222 A HUP0103222 A HU P0103222A HU P0103222 A2 HUP0103222 A2 HU P0103222A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- glucocorticoid
- treatment
- metabolic disorders
- hormone receptor
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 title 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 102000004217 thyroid hormone receptors Human genes 0.000 title 1
- 108090000721 thyroid hormone receptors Proteins 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 208000014311 Cushing syndrome Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- -1 methoxy, amino Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
- C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány az (I) általános képletű vegyületekre vonatkozik, aképletben R1 jelentése alifás vagy aromás szénhidrogéncsoport,karbonsavcsoport vagy -észtere, alkenilkarbonsavcsoport vagy észtere,hidroxilcsoport, halogénatom vagy cianocsoport vagy gyógyászatilagelfogadható sója és összes sztereoizomere; R2 és R3 jelentése azonosanvagy különbözően hidrogén- vagy halogénatom, alkil- vagycikloalkilcsoport, ahol az R2 és R3 helyettesítők legalább egyikehidrogénatomtól eltérő; X jelentése karbonil- vagy metiléncsoport; R4jelentése alifás, aromás vagy heteroaromás csoport; R5 jelentésehalogénatom, alkil- vagy cikloalkilcsoport; Y jelentése hidroxil-,metoxi-, amino- vagy alkilaminocsoport; n értéke 0 és 4 közötti egész szám. A találmány kiterjed ezenvegyületek glükokortikoid által szabályzott gének expressziójátólfüggő metabolizmus rendellenességek kezelésére, például cukorbaj,Cushing szindróma és gyulladás kezelésére történő alkalmazására. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9816935.2A GB9816935D0 (en) | 1998-08-05 | 1998-08-05 | Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders |
PCT/IB1999/001447 WO2000007972A1 (en) | 1998-08-05 | 1999-08-04 | Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0103222A2 true HUP0103222A2 (hu) | 2002-01-28 |
HUP0103222A3 HUP0103222A3 (en) | 2002-12-28 |
Family
ID=10836671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0103222A HUP0103222A3 (en) | 1998-08-05 | 1999-08-04 | Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
Country Status (26)
Country | Link |
---|---|
US (1) | US6492424B1 (hu) |
EP (1) | EP1102739B1 (hu) |
JP (1) | JP2002522407A (hu) |
KR (1) | KR20010072113A (hu) |
CN (1) | CN1311767A (hu) |
AT (1) | ATE238267T1 (hu) |
AU (1) | AU753376B2 (hu) |
BG (1) | BG105214A (hu) |
BR (1) | BR9912742A (hu) |
CA (1) | CA2339194A1 (hu) |
DE (1) | DE69907210T2 (hu) |
DK (1) | DK1102739T3 (hu) |
ES (1) | ES2193730T3 (hu) |
GB (1) | GB9816935D0 (hu) |
HU (1) | HUP0103222A3 (hu) |
ID (1) | ID28805A (hu) |
IL (1) | IL141106A0 (hu) |
MX (1) | MXPA01001047A (hu) |
NO (1) | NO20010610L (hu) |
PL (1) | PL345824A1 (hu) |
SE (1) | SE1102739T5 (hu) |
SI (1) | SI20579A (hu) |
SK (1) | SK942001A3 (hu) |
TR (1) | TR200100274T2 (hu) |
WO (1) | WO2000007972A1 (hu) |
ZA (1) | ZA200100832B (hu) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2363145C (en) | 1999-03-01 | 2006-02-14 | Pfizer Products Inc. | Oxamic acids and derivatives as thyroid receptor ligands |
US6599942B1 (en) | 1999-03-29 | 2003-07-29 | Novartis Ag | Thyromimetic organic compounds |
US6790978B2 (en) | 1999-03-29 | 2004-09-14 | Novartis Ag | Thyromimetic organic compounds |
GB9928805D0 (en) * | 1999-12-07 | 2000-02-02 | Karobio Ab | Compounds active at the Glucocorticoid and Thyroid Hormone Receptors |
US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
DE10038007A1 (de) * | 2000-08-04 | 2002-02-14 | Bayer Ag | Neue Amino-und Amido-Diphenylether für Arzneimittel |
DE60113032T2 (de) | 2000-10-30 | 2006-07-06 | Pfizer Products Inc., Groton | Glukokortikoidrezeptor-Modulatoren |
AU2001216038A1 (en) * | 2000-11-14 | 2002-05-27 | Alcon Laboratories Inc. | Treatment of glaucoma and ocular hypertension |
GB0029100D0 (en) * | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
GB0029102D0 (en) | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
US6583180B2 (en) | 2001-02-14 | 2003-06-24 | Abbott Laboratories | Glucocorticoid receptor modulators |
US6777442B2 (en) * | 2001-03-12 | 2004-08-17 | Bayer Aktiengesellschaft | Diphenyl derivatives |
GB0111861D0 (en) * | 2001-05-15 | 2001-07-04 | Karobio Ab | Novel compounds |
GB0120691D0 (en) * | 2001-08-24 | 2001-10-17 | Karobio Ab | Novel Compounds |
EP1499578A2 (en) | 2001-08-24 | 2005-01-26 | Karo Bio Ab | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
US6815555B2 (en) | 2001-09-26 | 2004-11-09 | Theravance, Inc. | Substituted phenol compounds useful for anesthesia and sedation |
EP1297833B1 (en) | 2001-09-26 | 2005-12-21 | Pfizer Products Inc. | Indole carboxylic acids as thyroid receptor ligands |
CA2473886C (en) | 2002-01-22 | 2012-08-21 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
JPWO2003064369A1 (ja) | 2002-01-30 | 2005-05-26 | キッセイ薬品工業株式会社 | 新規な甲状腺ホルモン受容体リガンド、それを含有する医薬組成物、およびそれらの用途 |
GB0215978D0 (en) * | 2002-07-10 | 2002-08-21 | Karobio Ab | Novel compounds |
AU2002951977A0 (en) | 2002-10-10 | 2002-10-24 | Leo Engineering Pty Ltd | Improvements to two-part vessels |
US7829552B2 (en) * | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
GB0406378D0 (en) * | 2004-03-22 | 2004-04-21 | Karobio Ab | Novel pharmaceutical compositions |
EP1890768A2 (en) * | 2005-05-26 | 2008-02-27 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
MX2007014502A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos para el tratamiento de enfermedades del higado graso. |
EP2273881A1 (en) * | 2008-04-15 | 2011-01-19 | Osteogenex, Inc. | Compounds and methods for altering bone growth |
EP3541395A4 (en) | 2016-11-21 | 2020-07-01 | Viking Therapeutics, Inc. | GLYCOGENOSIS TREATMENT METHODS |
US11707472B2 (en) | 2017-06-05 | 2023-07-25 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
CN112135832A (zh) | 2018-03-22 | 2020-12-25 | 维京治疗公司 | 化合物的晶型和制备化合物的晶型的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE159515T1 (de) * | 1992-07-21 | 1997-11-15 | Ciba Geigy Ag | Oxamidsäure-derivate als hypocholesterämische mittel |
EP1143948A3 (en) * | 1998-06-08 | 2002-09-11 | Karo Bio Ab | Liver-selective glucocorticoid antagonist for treating diabetes |
-
1998
- 1998-08-05 GB GBGB9816935.2A patent/GB9816935D0/en not_active Ceased
-
1999
- 1999-08-04 SE SE99936913T patent/SE1102739T5/xx unknown
- 1999-08-04 WO PCT/IB1999/001447 patent/WO2000007972A1/en not_active Application Discontinuation
- 1999-08-04 PL PL99345824A patent/PL345824A1/xx not_active Application Discontinuation
- 1999-08-04 DE DE69907210T patent/DE69907210T2/de not_active Expired - Fee Related
- 1999-08-04 IL IL14110699A patent/IL141106A0/xx unknown
- 1999-08-04 BR BR9912742-3A patent/BR9912742A/pt not_active Application Discontinuation
- 1999-08-04 KR KR1020017001279A patent/KR20010072113A/ko not_active Application Discontinuation
- 1999-08-04 HU HU0103222A patent/HUP0103222A3/hu unknown
- 1999-08-04 DK DK99936913T patent/DK1102739T3/da active
- 1999-08-04 AT AT99936913T patent/ATE238267T1/de not_active IP Right Cessation
- 1999-08-04 CN CN99809310A patent/CN1311767A/zh active Pending
- 1999-08-04 ID IDW20010257A patent/ID28805A/id unknown
- 1999-08-04 EP EP99936913A patent/EP1102739B1/en not_active Expired - Lifetime
- 1999-08-04 ES ES99936913T patent/ES2193730T3/es not_active Expired - Lifetime
- 1999-08-04 JP JP2000563607A patent/JP2002522407A/ja active Pending
- 1999-08-04 SK SK94-2001A patent/SK942001A3/sk unknown
- 1999-08-04 TR TR2001/00274T patent/TR200100274T2/xx unknown
- 1999-08-04 MX MXPA01001047A patent/MXPA01001047A/es not_active IP Right Cessation
- 1999-08-04 SI SI9920064A patent/SI20579A/sl unknown
- 1999-08-04 US US09/744,865 patent/US6492424B1/en not_active Expired - Fee Related
- 1999-08-04 AU AU51881/99A patent/AU753376B2/en not_active Ceased
- 1999-08-04 CA CA002339194A patent/CA2339194A1/en not_active Abandoned
-
2001
- 2001-01-30 ZA ZA200100832A patent/ZA200100832B/xx unknown
- 2001-02-02 BG BG105214A patent/BG105214A/xx unknown
- 2001-02-05 NO NO20010610A patent/NO20010610L/no unknown
Also Published As
Publication number | Publication date |
---|---|
SI20579A (sl) | 2001-12-31 |
CA2339194A1 (en) | 2000-02-17 |
TR200100274T2 (tr) | 2001-09-21 |
EP1102739B1 (en) | 2003-04-23 |
ZA200100832B (en) | 2001-10-31 |
NO20010610L (no) | 2001-04-04 |
SE1102739T5 (hu) | 2003-09-16 |
MXPA01001047A (es) | 2002-09-02 |
ES2193730T3 (es) | 2003-11-01 |
PL345824A1 (en) | 2002-01-14 |
DE69907210D1 (de) | 2003-05-28 |
AU753376B2 (en) | 2002-10-17 |
HUP0103222A3 (en) | 2002-12-28 |
EP1102739A1 (en) | 2001-05-30 |
BG105214A (en) | 2001-12-29 |
DE69907210T2 (de) | 2004-02-19 |
CN1311767A (zh) | 2001-09-05 |
DK1102739T3 (da) | 2003-08-18 |
BR9912742A (pt) | 2001-05-02 |
IL141106A0 (en) | 2002-02-10 |
ID28805A (id) | 2001-07-05 |
KR20010072113A (ko) | 2001-07-31 |
ATE238267T1 (de) | 2003-05-15 |
WO2000007972A1 (en) | 2000-02-17 |
JP2002522407A (ja) | 2002-07-23 |
NO20010610D0 (no) | 2001-02-05 |
SE1102739T3 (hu) | 2003-08-12 |
AU5188199A (en) | 2000-02-28 |
US6492424B1 (en) | 2002-12-10 |
GB9816935D0 (en) | 1998-09-30 |
SK942001A3 (en) | 2001-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0103222A2 (hu) | Anyagcsere rendellenességek kezelésére alkalmas glükokortikoid és tiroid hormon receptor ligandumok | |
HUP9802300A2 (hu) | N-heteroaril-piridin-szulfonamid származékok, ezeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk | |
EP1070710A3 (en) | Dithiolan derivatives, their preparation and their therapeutic effect | |
FI891548A (fi) | Administrering av monoaminakridiner i kolinergiska bristtillstaond av nervceller. | |
CA2315113A1 (en) | Pyridones as src family sh2 domain inhibitors | |
UA66864C2 (uk) | Похідні сечовини, фармацевтична композиція і спосіб лікування або профілактики запальних, аутоімунних або респіраторних захворювань | |
KR920008024A (ko) | 퀴놀린 유도체 | |
HUP0101192A2 (hu) | Cikloalkénszármazékok, előállításuk és alkalmazásuk | |
KR900004714A (ko) | 신규의 3,4-디아미노 퀴놀린 및 피리딘계 화합물 | |
NO995638D0 (no) | Heterobicykliske forbindelser til fremstilling av pyridonkarboksylsyrederivater | |
SE9102909L (sv) | Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms) | |
ES2008962A6 (es) | Proceso para la preparacion de nuevos compuestos de 2-guanidinotiazol | |
ES2034909A6 (es) | Metodo para la obtencion de derivados de 1h-azol-(w-(4-(2-pirimidinil)-1-piperazinil)-alquilo. | |
JPS57154129A (en) | Cardiotonic drug | |
AU539177B2 (en) | Amino alkoxy pyrazoles | |
KR900009640A (ko) | 벤족 사제핀 유도체 | |
CA2453991A1 (en) | New antitumoral derivatives of et-743 | |
HUP9900895A2 (hu) | Simaizom sejtburjánzást gátló 2-szubsztituált benzimidazolszármazékok | |
HUP9904498A2 (hu) | 17-Difluor-metilén-ösztra-triének alkalmazása lipoprotein(A) plazmaszintek csökkentésére | |
KR910006217A (ko) | 디히드로카페인산 유도체 및 이를 함유하는 약학제제 | |
JPS55120516A (en) | Antitumor drug comprising organic silicon compound as chief ingredient | |
EP0461264A4 (en) | Ethynylphenyl derivative, production thereof, and remedy for diseases of circulatory organs containing the same as active ingredient | |
CA2239053A1 (en) | Diphenyl pyridyl ethane derivatives as pde iv inhibitors | |
EP0755680A3 (en) | Use of piperazine compounds as narcotic antagonists | |
DE59008718D1 (de) | 5-(Amino)-triazolylcarbothioamidderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel sowie Verwendung der ersteren. |